| Hydroxychloroquine-mediated inhibition of SARS-CoV-2 entry is attenuated by TMPRSS2 T Ou, H Mou, L Zhang, A Ojha, H Choe, M Farzan PLoS pathogens 17 (1), e1009212, 2021 | 212 | 2021 |
| A reversible RNA on-switch that controls gene expression of AAV-delivered therapeutics in vivo G Zhong, H Wang, W He, Y Li, H Mou, ZJ Tickner, MH Tran, T Ou, Y Yin, ... Nature biotechnology 38 (2), 169-175, 2020 | 69 | 2020 |
| A more efficient CRISPR-Cas12a variant derived from Lachnospiraceae bacterium MA2020 MH Tran, H Park, CL Nobles, P Karunadharma, L Pan, G Zhong, H Wang, ... Molecular Therapy-Nucleic Acids 24, 40-53, 2021 | 23 | 2021 |
| Reprogramming of the heavy-chain CDR3 regions of a human antibody repertoire T Ou, W He, BD Quinlan, Y Guo, MH Tran, P Karunadharma, H Park, ... Molecular Therapy 30 (1), 184-197, 2022 | 10 | 2022 |
| In vitro affinity maturation of broader and more-potent variants of the HIV-1–neutralizing antibody CAP256-VRC26. 25 Y Yin, BD Quinlan, T Ou, Y Guo, W He, M Farzan Proceedings of the National Academy of Sciences 118 (29), e2106203118, 2021 | 8 | 2021 |
| Heavy-chain CDR3-engineered B cells facilitate in vivo evaluation of HIV-1 vaccine candidates W He, T Ou, N Skamangas, CC Bailey, N Bronkema, Y Guo, Y Yin, ... Immunity 56 (10), 2408-2424. e6, 2023 | 3 | 2023 |
| In vivo affinity maturation of mouse B cells reprogrammed to express human antibodies Y Yin, Y Guo, Y Jiang, B Quinlan, H Peng, G Crynen, W He, L Zhang, T Ou, ... Nature Biomedical Engineering, 1-19, 2024 | | 2024 |
| In vivo affinity maturation of the HIV-1 Env-binding domain of CD4 M Farzan, A Pan, C Bailey, T Ou, J Xu, X Liu, B Hu, G Crynen, ... | | 2024 |
| In vivo affinity maturation of the HIV-1 Env-binding domain of CD4 A Pan, CC Bailey, T Ou, J Xu, X Liu, B Hu, G Crynen, N Skamangas, ... bioRxiv, 2024.02. 03.578630, 2024 | | 2024 |
| In vivo affinity maturation of murine B cells reprogrammed to express human antibodies Y Yin, Y Guo, Y Jiang, B Quinlan, H Peng, G Crynen, W He, L Zhang, T Ou, ... bioRxiv, 2023 | | 2023 |
| PP 2.16–00177 Development of a nonhuman primate model to study the immunological effects of feminizing hormone therapy in transgender women P Hahn, E Alexander, K Weisgrau, E Rakasz, J Kurian, T Ou, W He, ... | | 2022 |
| Efficient reprogramming of the heavy-chain CDR3 regions of a human antibody repertoire T Ou, W He, BD Quinlan, Y Guo, P Karunadharma, H Park, ... bioRxiv, 2021.04. 01.437943, 2021 | | 2021 |
| Hydroxychloroquine-mediated inhibition of SARS-CoV-2 entry is attenuated by TMPRSS2 (preprint) T Ou, H Mou, L Zhang, A Ojha, H Choe, M Farzan | | 2020 |
